Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.
Wenli LiuAiham QdaisatRenata FerrarottoClifton D FullerMing GuoLarissa A MeyerSanthosshi NarayananGabriel LopezLorenzo G CohenEduardo BrueraEhab Y HannaSai-Ching Jim YeungPublished in: Cancer (2020)
The frequency and severity of hypomagnesemia during treatment are prognostic of survival for patients with head and neck cancers who are receiving concurrent chemoradiation with cisplatin and/or carboplatin. A prospective study is needed to investigate the impact of the prevention of hypomagnesemia on survival in this patient population.